Cytosorbents Crp
$ 0.62
-7.43%
11 Feb - close price
- Market Cap 38,951,200 USD
- Current Price $ 0.62
- High / Low $ 0.68 / 0.62
- Stock P/E N/A
- Book Value 0.14
- EPS -0.17
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.93 %
- 52 Week High 1.61
- 52 Week Low 0.60
About
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Analyst Target Price
$5.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-07 | 2025-05-07 | 2025-03-12 | 2024-11-07 | 2024-08-02 | 2024-05-09 | 2024-03-14 | 2023-11-10 | 2023-08-01 | 2023-05-02 | 2023-03-09 |
| Reported EPS | -0.04 | 0.03 | -0.1441 | -0.14 | -0.04 | -0.08 | -0.12 | -0.13 | -0.21 | -0.14 | -0.17 | -0.02 |
| Estimated EPS | -0.05 | -0.04 | -0.07 | -0.0533 | -0.06 | -0.1 | -0.12 | -0.14 | -0.14 | -0.11 | -0.13 | -0.17 |
| Surprise | 0.01 | 0.07 | -0.0741 | -0.0867 | 0.02 | 0.02 | 0 | 0.01 | -0.07 | -0.03 | -0.04 | 0.15 |
| Surprise Percentage | 20% | 175% | -105.8571% | -162.6642% | 33.3333% | 20% | 0% | 7.1429% | -50% | -27.2727% | -30.7692% | 88.2353% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTSO
2026-01-16 03:57:31
CytoSorbents announced preliminary unaudited Q4 and full-year 2025 results, with revenues expected to be approximately $9.2 million and $37.0 million respectively, alongside strong gross margins. Key business updates include the acceptance of STAR-T study results for publication, a scheduled FDA Pre-Submission Meeting for DrugSorb®-ATR, and surpassing 300,000 cumulative CytoSorb treatments worldwide. The company is also implementing strategic workforce and cost reductions, aiming for cash-flow breakeven in Q1 2026.
2026-01-12 13:27:47
CytoSorbents (NASDAQ:CTSO) expects Q4 2025 revenue of approximately $9.2 million and full-year 2025 revenue of around $37 million, marking a 4% annual increase. The company also announced that its CytoSorb treatments have surpassed 300,000 worldwide and reported improved gross margins for 2025. Additionally, CytoSorbents plans a Pre-Submission Meeting with the FDA for its DrugSorb-ATR device, with a De Novo Application filing anticipated by Q1 2026.
2026-01-10 15:27:15
CytoSorbents announced preliminary unaudited Q4 and full-year 2025 financial results, with estimated revenues of $9.2 million and $37.0 million respectively. The company also provided a business update, including planned FDA meetings for its DrugSorb®-ATR device and the acceptance of STAR-T study results for publication. Management highlighted strategic workforce reductions and credit agreement amendments aimed at achieving cash-flow breakeven in Q1 2026.
2025-12-16 19:09:56
D. Boral Capital analyst Jason Kolbert has reaffirmed a "Buy" rating for CytoSorbents (CTSO) with an unchanged price target of $10, signaling continued confidence in the company's prospects. This outlook is consistent with previous evaluations. Wall Street analysts forecast an average target price of $5.25 for CTSO, implying a significant upside from its current price.
2025-12-11 02:09:56
CytoSorbents Corporation announced that its CEO, Dr. Phillip Chan, and CFO, Peter J. Mariani, will participate in a virtual fireside chat with D. Boral Capital on Monday, December 15, 2025. The discussion will cover recent Q3 earnings, including $37.0 million in trailing 12-month sales, a strengthened balance sheet, and regulatory progress for DrugSorb™-ATR with the FDA, with a key decision expected mid-2026. The chat aims to provide additional insights into these developments and other milestones driving the company's growth.
2025-12-10 22:08:52
CytoSorbents announced a virtual fireside chat for December 15, 2025, featuring CEO Dr. Phillip Chan and CFO Peter J. Mariani, to discuss recent developments including $37.0 million in trailing 12-month high-margin sales. The discussion will also cover ongoing regulatory progress for DrugSorb-ATR, with an FDA decision anticipated in mid-2026, and other milestones shaping the company's growth. The event will provide further insights into their Q3 results and near-term objectives.
